Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹372.28 Cr
Profit after tax
₹50.58 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations372.28+15.03%1,365.47
Other income5.19+86.60%16.33
Total income377.47+15.64%1,381.80
Employee benefit expense85.24+17.85%297.44
Finance costs4.77+11.17%19.19
Depreciation & amortisation27.81−0.19%116.17
Total expenses311.09+11.61%1,162.60
Profit before tax66.38+39.20%211.24
Tax expense15.72+29.93%54.10
Profit after tax50.58+42.16%157.48
Total comprehensive income50.63+43.98%157.31
Earnings per share
Earnings per share, basic₹2.44₹7.62
Earnings per share, diluted₹2.44₹7.62

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Metropolis Healthcare reported Q1 FY27 revenue growth of approximately 17% year-on-year to Rs 450 crores, driven primarily by volume growth, with EBITDA margin expanding 210 basis points to 25.2%. Patient volumes grew 10% and test volumes grew 11%, with no price increases taken over the last 18 months. Management discussed integration progress on Core Diagnostics, network expansion in Tier-2 and Tier-3 towns, and performance across B2C, B2B, Specialty and TruHealth segments.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 48 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 20 Aug 2026.